XML 59 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenues (Revenues Disaggregated by Significant Customer) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues	$ 228,602	$ 225,397	$ 186,108	$ 213,719	$ 120,072	$ 152,510	$ 99,008	$ 80,887	$ 853,826	$ 452,477	$ 191,454
Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									100.00%	100.00%	100.00%
Ipsen
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 182,879	$ 69,792	$ 33,252
Ipsen | Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									21.00%	15.00%	17.00%
Caremark L.L.C.
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 110,698	$ 73,921	$ 17,746
Caremark L.L.C. | Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									13.00%	16.00%	9.00%
Affiliates of McKesson Corporation
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 99,916	$ 48,662	$ 13,143
Affiliates of McKesson Corporation | Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									12.00%	11.00%	7.00%
Accredo Health, Incorporated
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 81,028	$ 50,716	$ 16,631
Accredo Health, Incorporated | Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									9.00%	11.00%	9.00%
Diplomat Specialty Pharmacy
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 74,244	$ 83,059	$ 63,826
Diplomat Specialty Pharmacy | Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									9.00%	18.00%	33.00%
Others, individually less than 10% of Total revenues for all periods presented
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenues									$ 305,061	$ 126,327	$ 46,856
Others, individually less than 10% of Total revenues for all periods presented | Sales revenue, net | Customer concentration risk
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total									36.00%	29.00%	25.00%

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_IpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_OtherCustomersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: